Guardant Health Inc (GH)

$36.03 $0.50 (1.41%) 12:07 PM 12/11/24
NASDAQ | $USD | Diagnostics & Research

Stock Data

  • Market Cap

    $4.56B
  • Day's Range

    $35.49 - $36.34
  • Volume

    1,611,976
  • 52 Week Low / High

    $15.81 - $38.53
  • PE Ratio

    -
  • PEG Ratio

    -
  • Dividend Frequency

    monthly

GH's Dividend
$0.03
Amount
1.21%
Dividend Yield
Feb 15
Payment Date
$0.36
Annual Dividend Amount
Dividend Streak
Hypothetical 10k Investment Jan 1, 2020
Capital Growth
Dividend Return to Date
Dividend Payout year Est.
Expenses
Total Return
Total Return %
Analyists Ranking
14
Strong Buy
7
Buy
1
Hold
0
Sell
0
Strong Sell
$53.00
Target Price

Company News

  • FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test — Oct 4th, 2024

    FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test On Friday, the FDA approved Exact Sciences Corp.’s (NASDAQ:EXAS) Cologuard Plus test, the company’s next-generation multi-target stool DNA test. The Cologuard Plus test is now approved for adults ages 45 and...

  • Guardant Health Stock Sees RS Rating Jump To 83 — Nov 20th, 2024

    On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83. This exclusive rating from Investor's Business Daily measures price action with a 1 (worst) to 99 (best) score. Continue reading View comments...

  • FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test — Oct 4th, 2024

    FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test On Friday, the FDA approved Exact Sciences Corp.’s (NASDAQ:EXAS) Cologuard Plus test, the company’s next-generation multi-target stool DNA test. The Cologuard Plus test is now approved for adults ages 45 and...

  • Why Guardant Health Stock Was the Picture of Health Today — Oct 30th, 2024

    There's nothing like free publicity to help goose the sales of a relatively new product....

  • Guardant Health Stock Sees RS Rating Jump To 83 — Nov 20th, 2024

    On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83. This exclusive rating from Investor's Business Daily measures price action with a 1 (worst) to 99 (best) score. Continue reading View comments...

  • Guardant Health to Report Third Quarter 2024 Financial Results on November 6, 2024 — Oct 15th, 2024

    PALO ALTO, Calif., October 15, 2024--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, November 6, 2024. Company management will webcast a c...

  • Is There An Opportunity With Guardant Health, Inc.'s (NASDAQ:GH) 43% Undervaluation? — Oct 18th, 2024

    Key Insights Guardant Health's estimated fair value is US$36.20 based on 2 Stage Free Cash Flow to Equity Guardant Health is estimated to be 43% undervalued based on current share price of US$20.68 Analyst price target for GH is US$42.05, which is 16% above our fair value estimate In thi...

  • Is There An Opportunity With Guardant Health, Inc.'s (NASDAQ:GH) 43% Undervaluation? — Oct 18th, 2024

    Key Insights Guardant Health's estimated fair value is US$36.20 based on 2 Stage Free Cash Flow to Equity Guardant Health is estimated to be 43% undervalued based on current share price of US$20.68 Analyst price target for GH is US$42.05, which is 16% above our fair value estimate In thi...

  • Guardant Health Stock Sees RS Rating Jump To 83 — Nov 20th, 2024

    On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83. This exclusive rating from Investor's Business Daily measures price action with a 1 (worst) to 99 (best) score. Continue reading View comments...

  • Is There An Opportunity With Guardant Health, Inc.'s (NASDAQ:GH) 43% Undervaluation? — Oct 18th, 2024

    Key Insights Guardant Health's estimated fair value is US$36.20 based on 2 Stage Free Cash Flow to Equity Guardant Health is estimated to be 43% undervalued based on current share price of US$20.68 Analyst price target for GH is US$42.05, which is 16% above our fair value estimate In thi...

  • Guardant Health to Report Third Quarter 2024 Financial Results on November 6, 2024 — Oct 15th, 2024

    PALO ALTO, Calif., October 15, 2024--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, November 6, 2024. Company management will webcast a c...

  • FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test — Oct 4th, 2024

    FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test On Friday, the FDA approved Exact Sciences Corp.’s (NASDAQ:EXAS) Cologuard Plus test, the company’s next-generation multi-target stool DNA test. The Cologuard Plus test is now approved for adults ages 45 and...

  • Why Guardant Health Stock Was the Picture of Health Today — Oct 30th, 2024

    There's nothing like free publicity to help goose the sales of a relatively new product....

  • Guardant Health to Report Third Quarter 2024 Financial Results on November 6, 2024 — Oct 15th, 2024

    PALO ALTO, Calif., October 15, 2024--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, November 6, 2024. Company management will webcast a c...

  • Guardant Health Stock Sees RS Rating Jump To 83 — Nov 20th, 2024

    On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83. This exclusive rating from Investor's Business Daily measures price action with a 1 (worst) to 99 (best) score. Continue reading View comments...

  • Why Guardant Health Stock Was the Picture of Health Today — Oct 30th, 2024

    There's nothing like free publicity to help goose the sales of a relatively new product....

  • Guardant Health Stock Sees RS Rating Jump To 83 — Nov 20th, 2024

    On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83. This exclusive rating from Investor's Business Daily measures price action with a 1 (worst) to 99 (best) score. Continue reading View comments...

  • Is There An Opportunity With Guardant Health, Inc.'s (NASDAQ:GH) 43% Undervaluation? — Oct 18th, 2024

    Key Insights Guardant Health's estimated fair value is US$36.20 based on 2 Stage Free Cash Flow to Equity Guardant Health is estimated to be 43% undervalued based on current share price of US$20.68 Analyst price target for GH is US$42.05, which is 16% above our fair value estimate In thi...

  • Guardant Health Stock Sees RS Rating Jump To 83 — Nov 20th, 2024

    On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83. This exclusive rating from Investor's Business Daily measures price action with a 1 (worst) to 99 (best) score. Continue reading View comments...

  • Why Guardant Health Stock Was the Picture of Health Today — Oct 30th, 2024

    There's nothing like free publicity to help goose the sales of a relatively new product....

  • Guardant Health Stock Sees RS Rating Jump To 83 — Nov 20th, 2024

    On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83. This exclusive rating from Investor's Business Daily measures price action with a 1 (worst) to 99 (best) score. Continue reading View comments...

  • FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test — Oct 4th, 2024

    FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test On Friday, the FDA approved Exact Sciences Corp.’s (NASDAQ:EXAS) Cologuard Plus test, the company’s next-generation multi-target stool DNA test. The Cologuard Plus test is now approved for adults ages 45 and...

  • Guardant Health Stock Sees RS Rating Jump To 83 — Nov 20th, 2024

    On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83. This exclusive rating from Investor's Business Daily measures price action with a 1 (worst) to 99 (best) score. Continue reading View comments...

  • Guardant Health Stock Sees RS Rating Jump To 83 — Nov 20th, 2024

    On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83. This exclusive rating from Investor's Business Daily measures price action with a 1 (worst) to 99 (best) score. Continue reading View comments...

  • Why Guardant Health Stock Was the Picture of Health Today — Oct 30th, 2024

    There's nothing like free publicity to help goose the sales of a relatively new product....

  • Guardant Health Stock Sees RS Rating Jump To 83 — Nov 20th, 2024

    On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83. This exclusive rating from Investor's Business Daily measures price action with a 1 (worst) to 99 (best) score. Continue reading View comments...

  • Guardant Health to Report Third Quarter 2024 Financial Results on November 6, 2024 — Oct 15th, 2024

    PALO ALTO, Calif., October 15, 2024--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, November 6, 2024. Company management will webcast a c...

  • Is There An Opportunity With Guardant Health, Inc.'s (NASDAQ:GH) 43% Undervaluation? — Oct 18th, 2024

    Key Insights Guardant Health's estimated fair value is US$36.20 based on 2 Stage Free Cash Flow to Equity Guardant Health is estimated to be 43% undervalued based on current share price of US$20.68 Analyst price target for GH is US$42.05, which is 16% above our fair value estimate In thi...

  • FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test — Oct 4th, 2024

    FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test On Friday, the FDA approved Exact Sciences Corp.’s (NASDAQ:EXAS) Cologuard Plus test, the company’s next-generation multi-target stool DNA test. The Cologuard Plus test is now approved for adults ages 45 and...

  • FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test — Oct 4th, 2024

    FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test On Friday, the FDA approved Exact Sciences Corp.’s (NASDAQ:EXAS) Cologuard Plus test, the company’s next-generation multi-target stool DNA test. The Cologuard Plus test is now approved for adults ages 45 and...

  • Guardant Health Stock Sees RS Rating Jump To 83 — Nov 20th, 2024

    On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83. This exclusive rating from Investor's Business Daily measures price action with a 1 (worst) to 99 (best) score. Continue reading View comments...

  • Is There An Opportunity With Guardant Health, Inc.'s (NASDAQ:GH) 43% Undervaluation? — Oct 18th, 2024

    Key Insights Guardant Health's estimated fair value is US$36.20 based on 2 Stage Free Cash Flow to Equity Guardant Health is estimated to be 43% undervalued based on current share price of US$20.68 Analyst price target for GH is US$42.05, which is 16% above our fair value estimate In thi...

  • Is There An Opportunity With Guardant Health, Inc.'s (NASDAQ:GH) 43% Undervaluation? — Oct 18th, 2024

    Key Insights Guardant Health's estimated fair value is US$36.20 based on 2 Stage Free Cash Flow to Equity Guardant Health is estimated to be 43% undervalued based on current share price of US$20.68 Analyst price target for GH is US$42.05, which is 16% above our fair value estimate In thi...

  • Is There An Opportunity With Guardant Health, Inc.'s (NASDAQ:GH) 43% Undervaluation? — Oct 18th, 2024

    Key Insights Guardant Health's estimated fair value is US$36.20 based on 2 Stage Free Cash Flow to Equity Guardant Health is estimated to be 43% undervalued based on current share price of US$20.68 Analyst price target for GH is US$42.05, which is 16% above our fair value estimate In thi...

  • FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test — Oct 4th, 2024

    FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test On Friday, the FDA approved Exact Sciences Corp.’s (NASDAQ:EXAS) Cologuard Plus test, the company’s next-generation multi-target stool DNA test. The Cologuard Plus test is now approved for adults ages 45 and...

  • Guardant Health Stock Sees RS Rating Jump To 83 — Nov 20th, 2024

    On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83. This exclusive rating from Investor's Business Daily measures price action with a 1 (worst) to 99 (best) score. Continue reading View comments...

  • FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test — Oct 4th, 2024

    FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test On Friday, the FDA approved Exact Sciences Corp.’s (NASDAQ:EXAS) Cologuard Plus test, the company’s next-generation multi-target stool DNA test. The Cologuard Plus test is now approved for adults ages 45 and...

  • FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test — Oct 4th, 2024

    FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test On Friday, the FDA approved Exact Sciences Corp.’s (NASDAQ:EXAS) Cologuard Plus test, the company’s next-generation multi-target stool DNA test. The Cologuard Plus test is now approved for adults ages 45 and...

  • Guardant Health Stock Sees RS Rating Jump To 83 — Nov 20th, 2024

    On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83. This exclusive rating from Investor's Business Daily measures price action with a 1 (worst) to 99 (best) score. Continue reading View comments...

  • Guardant Health to Report Third Quarter 2024 Financial Results on November 6, 2024 — Oct 15th, 2024

    PALO ALTO, Calif., October 15, 2024--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, November 6, 2024. Company management will webcast a c...

  • Is There An Opportunity With Guardant Health, Inc.'s (NASDAQ:GH) 43% Undervaluation? — Oct 18th, 2024

    Key Insights Guardant Health's estimated fair value is US$36.20 based on 2 Stage Free Cash Flow to Equity Guardant Health is estimated to be 43% undervalued based on current share price of US$20.68 Analyst price target for GH is US$42.05, which is 16% above our fair value estimate In thi...

  • Guardant Health to Report Third Quarter 2024 Financial Results on November 6, 2024 — Oct 15th, 2024

    PALO ALTO, Calif., October 15, 2024--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, November 6, 2024. Company management will webcast a c...

  • Guardant Health Stock Sees RS Rating Jump To 83 — Nov 20th, 2024

    On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83. This exclusive rating from Investor's Business Daily measures price action with a 1 (worst) to 99 (best) score. Continue reading View comments...

  • Guardant Health to Report Third Quarter 2024 Financial Results on November 6, 2024 — Oct 15th, 2024

    PALO ALTO, Calif., October 15, 2024--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, November 6, 2024. Company management will webcast a c...

  • Is There An Opportunity With Guardant Health, Inc.'s (NASDAQ:GH) 43% Undervaluation? — Oct 18th, 2024

    Key Insights Guardant Health's estimated fair value is US$36.20 based on 2 Stage Free Cash Flow to Equity Guardant Health is estimated to be 43% undervalued based on current share price of US$20.68 Analyst price target for GH is US$42.05, which is 16% above our fair value estimate In thi...

  • Guardant Health to Report Third Quarter 2024 Financial Results on November 6, 2024 — Oct 15th, 2024

    PALO ALTO, Calif., October 15, 2024--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, November 6, 2024. Company management will webcast a c...

Similar Stocks

Want to be notified on dividend changes?

Start manging your portfolio today.

Sign up for free